The existence of an inositide-dependent nuclear signaling has been clearly shown. In this review we focused on the nuclear PI-PLC signaling activity and its downstream effects. The main isoform present in the nucleus is PI-PLC β1 and this isoform resides in the nuclear domains called speckles and colocalizes with the splicing factor SC35. PI-PLC β1 is also involved in the physiological control of the cell cycle. Moreover, acting on the cyclin D3 promoter plays a crucial role in the process of C2C12 myoblast differentiation. Finally in hematological malignancies such as high-risk MDS, the deletion of PI-PLC β1 gene has been observed. There is the likelihood that the deletion is a prognostic marker in that 66.7% MDS patients bearing the PI-PLC β1 monoallelic deletion evolved into AML. In addition the expression of nuclear PI-PLC β1 in MDS patients is modulated by the demethylating drug azacytidine. Therefore the analysis of nuclear PI-PLC-β1 appears useful for both MDS prognosis and checking of the epigenetic effect of antileukemic drugs.

Cocco L, Faenza I, Follo MY, Billi AM, Ramazzotti G, Papa V, et al. (2009). Nuclear inositides: PI-PLC signaling in cell growth, differentiation and pathology.. AMSTERDAM : ELSEVIER [10.1016/j.advenzreg.2008.12.001].

Nuclear inositides: PI-PLC signaling in cell growth, differentiation and pathology.

COCCO, LUCIO ILDEBRANDO;FAENZA, IRENE;FOLLO, MATILDE YUNG;BILLI, ANNA MARIA;RAMAZZOTTI, GIULIA;MARTELLI, ALBERTO MARIA;MANZOLI, LUCIA
2009

Abstract

The existence of an inositide-dependent nuclear signaling has been clearly shown. In this review we focused on the nuclear PI-PLC signaling activity and its downstream effects. The main isoform present in the nucleus is PI-PLC β1 and this isoform resides in the nuclear domains called speckles and colocalizes with the splicing factor SC35. PI-PLC β1 is also involved in the physiological control of the cell cycle. Moreover, acting on the cyclin D3 promoter plays a crucial role in the process of C2C12 myoblast differentiation. Finally in hematological malignancies such as high-risk MDS, the deletion of PI-PLC β1 gene has been observed. There is the likelihood that the deletion is a prognostic marker in that 66.7% MDS patients bearing the PI-PLC β1 monoallelic deletion evolved into AML. In addition the expression of nuclear PI-PLC β1 in MDS patients is modulated by the demethylating drug azacytidine. Therefore the analysis of nuclear PI-PLC-β1 appears useful for both MDS prognosis and checking of the epigenetic effect of antileukemic drugs.
2009
Advances in Enzyme Regulation 49
2
10
Cocco L, Faenza I, Follo MY, Billi AM, Ramazzotti G, Papa V, et al. (2009). Nuclear inositides: PI-PLC signaling in cell growth, differentiation and pathology.. AMSTERDAM : ELSEVIER [10.1016/j.advenzreg.2008.12.001].
Cocco L; Faenza I; Follo MY; Billi AM; Ramazzotti G; Papa V; Martelli AM; Manzoli L
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/82228
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 32
  • ???jsp.display-item.citation.isi??? 29
social impact